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Abstract
Introduction
The purpose of this study was to describe the prevalence
of obesity among American Indian and Alaska Native
(AI/AN) adults with diabetes and to examine the temporal
trends for class I, II, and III obesity in this high-risk group
during a 10-year period.
Methods
We used data on body mass index (BMI) from the annu-
al Diabetes Care and Outcomes Audit to estimate the
prevalence of class I, II, and III obesity (class I = 30.0–34.9
kg/m2, class II = 35.0–39.9 kg/m2, and class III >40.0
kg/m2) in each year from 1995 through 2004. We also
investigated trends in mean BMI during the 10-year peri-
od and the role of treatment in these trends using multi-
variable linear regression models.
Results
Obesity was highly prevalent in this population in 2004
(class I, 28.9%; class II, 20.4%; class III, 20.3%). From 1995
through 2004, the percentage of obese adults increased
from 16.7% to 20.4% in class II and 11.5% to 20.3% in class
III (P <.001), and the mean BMI increased from 32.1 kg/m2
to 34.4 kg/m2. The increase in BMI was greater in the
younger age groups. Adjusted mean BMI increased signifi-
cantly over 10 years for each of three treatment categories.
Conclusion
Extreme degrees of obesity are a common and increasing
problem among AI/AN adults with diabetes. We did not
find an association between the type of diabetes treatment
and the trend toward extreme degrees of obesity. The
increase in extreme obesity could potentially affect the
burden of morbidity and mortality among AI/AN adults
with diabetes. Effective and culturally appropriate weight
management interventions are needed.
Introduction
Obese individuals are at particularly high risk for car-
diovascular disease (CVD) and are also at increased risk
for other serious medical conditions, including hyperten-
sion, certain forms of cancer, arthritis, sleep and breathing
disorders, and gallbladder disease (1,2). Thus, obesity is an
important risk factor for adverse health outcomes and a
marker of increased health care cost. Evidence suggests
that obesity can be treated (3-5). Short-term weight loss
has been demonstrated to ameliorate obesity-related meta-
bolic abnormalities and CVD risk factors (6), and at least
one prospective randomized study is underway to examine
the long-term consequences of intentional weight loss in
overweight or obese people with diabetes (7). Although obe-
sity is a major public health issue that will continue to
require public health approaches aimed at preventing it,
our knowledge and ability to apply patient-directed inter-
ventions is increasing and holds promise for people now
affected.
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The current epidemic of type 2 diabetes in the United
States is largely a consequence of the epidemic of obesity,
and weight reduction remains a cornerstone of therapy for
people with diabetes (8,9). The Indian Health Service
(IHS), a federally operated health care system, provides
care to more than 1.5 million American Indian and Alaska
Native (AI/AN) people, of whom more than 100,000 have
diabetes (10). The extent and severity of obesity among
AI/AN people with diabetes, however, has not been exam-
ined. Understanding the magnitude of the coexistence of
these conditions could improve our ability to plan for med-
ical services and estimate health care expenditures for this
population at high risk for poor health.
The IHS conducts an annual system-wide assessment of
services for and outcomes of AI/AN people with diabetes
receiving services within the Indian health care system.
Using this data source, we were able to describe the bur-
den of obesity and the temporal trends in obesity among
adults during a 10-year period.
Methods
Data source
We conducted a cross-sectional study using data collect-
ed annually during 10 years at health care facilities that
collectively form a federally funded health care system for
AI/AN people. The facilities include federally operated IHS
hospitals, ambulatory clinics, health stations, and clinics
from all 12 administrative IHS areas as well as facilities
operated directly by tribal governments through contracts
or compacts with the IHS. The system also includes
American Indian organizations that provide services to
AI/AN people residing in 34 urban metropolitan areas.
The Diabetes Care and Outcomes Audit (DCOA) is con-
ducted annually by the IHS (11,12). The DCOA is per-
formed at the facility level and is used for local feedback
and performance improvement activities. At each partici-
pating facility, a systematic sample of medical records is
selected from all patients with diabetes (13). A local dia-
betes coordinator abstracts information from the selected
records using a standardized form covering more than 70
demographic and quality-of-care indicators. In some facili-
ties, the DCOA is created using a computer application
developed by the IHS that collects data from the facility’s
health information system.
Voluntary, nonpunitive reporting of local audit results to
the IHS Division of Diabetes Treatment and Prevention
provides an opportunity for aggregation of diabetes care
and outcomes measures into a national data set.
Participation in national reporting among the approxi-
mately 300 facilities in the IHS system is high. During the
period of this study, the number of facilities submitting
data ranged from a low of 145 in 1996 to a high of 281 in
2004. The number of patients in the annual reports ranged
from a low of 9557 in 1995 to a high of 33,769 in 2004. The
increase in the sample size reflects several temporal trends
in the audit process. An increased number of facilities par-
ticipated in the audit, and an increase in the prevalence of
diabetes resulted in a greater number of patients sampled
at each facility. Also, the use of electronic auditing tech-
niques appears to have increased the proportion of records
audited at many of the facilities using electronic auditing.
However, the criteria used for inclusion in the DCOA and
the criteria for data collection in the audit did not change
during the study period, and there was good comparability
between manual and electronic record review for programs
using electronic data auditing.
Of the potential records of patients aged 18 years and
older who were included in the DCOA from 1995 through
2004, 156,080 records had information necessary to calcu-
late body mass index (BMI). Of these records, 70 had an
implausible BMI (<15.0 kg/m2) and were excluded from
the analyses, leaving 156,010 records. Of these, 17,674
records were missing data on duration of diabetes and
treatment type and were excluded from the analyses. A
total of 138,336 records (88.6% of all records) were used for
analysis.
Outcome variable
BMI was calculated from recorded height and weight.
Obesity was categorized by grouping BMI values in the fol-
lowing categories: normal weight (<25.0 kg/m2), over-
weight (25.0–29.9 kg/m2), class I obesity (30.0–34.9
kg/m2), class II obesity (35.0–39.9 kg/m2), and class III
obesity (>40.0 kg/m2) (14).
Covariates
Demographic and clinical variables collected through the
DCOA included sex, age, duration of diabetes, treatment
type, and treatment facility. Age was calculated as the
date of audit minus the date of birth. Duration of diabetes
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recorded as diet or exercise alone (no medication), oral
agent(s), insulin, and oral agent plus insulin (combined
with the insulin group for purposes of analyses).
Treatment facility was recorded as the location where
patients obtained treatment and audit data was collected.
Data analyses
We conducted a descriptive analysis of BMI by demo-
graphic and clinical variables and by calendar year for all
people with measured heights and weights and calculated
BMI >15 kg/m2. We used analysis of covariance techniques
to estimate least square mean BMI values and to test the
hypotheses that BMI differed by age and calendar period.
The analyses were adjusted for age, sex, duration of dia-
betes, treatment type, and treatment facility. Tests for
temporal trends in obesity categories were conducted using
logistic regression techniques and were adjusted for age,
sex, duration of diabetes, treatment type, and treatment
facility. All statistical analyses were conducted using SAS
software (SAS Institute Inc, Cary, NC) (15).
Results
We found that obesity was a common and increasingly
prevalent problem among people with type 2 diabetes. In
1995, 59.2% of adults with diabetes were obese. By 2004,
69.6% of adults with diabetes were obese. Table 1 summa-
rizes selected demographic and clinical measures of AI/AN
adults with diabetes. Consistent with sex differences in the
prevalence of diabetes in AI/AN adults, more women than
men were included in the sample (16). Most patients used
oral agents either alone or in combination with other oral
agents. The average age at onset did not differ during the
study period. The unadjusted mean BMI increased signifi-
cantly from 32.1 in 1995 to 34.4 in 2004 (P < .001) (Table
1). Adjustment for age, sex, duration of diabetes, treatment
type, and treatment facility did not significantly change
this trend.
The prevalence of class II and class III obesity was high-
er in women than men in each year of the study (Table 2).
The prevalence of class II and class III obesity increased
from 1995 to 2004 (P < .001) in both men and women; how-
ever, the prevalence of class II and class III obesity
increased significantly more for men than women, thus
narrowing the sex difference. These trends were consis-
tently observed among 11 of 12 IHS administrative areas.
An increase in BMI was observed among all age groups
from 1995 through 2004. The adjusted mean BMI was
inversely related to age; the younger the age group, the
higher the adjusted mean BMI (P = .04) (Figure). In 2004,
for age category 18 to 39, the adjusted mean BMI was 37.0;
for 40 to 49, 36.2; for 50 to 59, 34.9; for 60 to 69, 33.2; and
for 70 years and older, 31.7. The increase in BMI during
the study period was greater in the younger age groups (P<
.001). Because the DCOA also contained information on
diabetes treatment, we were able to investigate potential
associations between obesity and type of treatment.
Adjusted mean BMI increased significantly for each treat-
ment category from 1995 through 2004 (Table 3).
Additional analyses that included records with missing
data did not substantially change the results (data not
shown).
Discussion
We found that the prevalence of obesity, as measured by
BMI, increased among AI/AN adults with diabetes during
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Figure. Adjusted mean body mass index (BMI [kg/m2]) by age among
American Indian and Alaska Native adults with diabetes, Diabetes Care and
Outcomes Audit, Indian Health Service, 1995–2004. Mean was adjusted
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the study period. A greater increase in BMI was observed
among adults in the younger age categories. We found a
greater percentage increase in obesity among men relative
to women. While the sex difference in the prevalence of
obesity has decreased, women remained more obese than
men in every year studied. Notably, the increase in obesi-
ty has resulted in a large increase in the proportion of peo-
ple with the most extreme degree of obesity.
The trends in obesity observed in this study may have
important clinical and public health implications. The
combination of diabetes and high BMI has been associated
with increased risk for the development of more severe
degrees of hyperglycemia, hypertension, dyslipidemia,
retinopathy, and progressive loss of renal function (17-19).
The relationship between obesity and cardiovascular dis-
ease morbidity and mortality are complex and nonlinear;
however, obesity in its most extreme degrees is associated
with higher all-cause and possible coronary cardiovascular
disease mortality (20,21). The increase in obesity among
adults with diabetes in this study could have implications
for the burden of morbidity and mortality among AI/AN
people with diabetes.
Obesity has been increasing among U.S. adults. Analysis
of Behavioral Risk Factor Surveillance System (BRFSS)
data shows a trend of increasing prevalence of extreme
obesity compared with other classes of obesity in the U.S.
population (22). BRFFS data and American Indian over-
samples have described similar trends among American
Indian adults. Between 1999 and 2003, 1000 American
Indian adults aged 18 years and older living on or near the
seven reservations in Montana were interviewed each year
using an adapted BRFSS survey. During this period, the
prevalence of obesity increased from 34% to 39% (23). The
Strong Heart Study, an epidemiological study of cardio-
vascular disease risk factors in four American Indian com-
munities, also documented the high prevalence of obesity,
particularly among participants in the younger age groups
(24). The trends in obesity in our study are also consistent
with trends in the prevalence of obesity and extreme obe-
sity among people with diabetes. Among adults with dia-
betes in an epidemiologic study in Rochester, Minn, the
proportion of obesity increased from 33% to 49%, and
extreme obesity nearly doubled from 5% to 9% over
approximately 20 years (21).
Because our study was cross-sectional, we cannot deter-
mine the cause or causes of our observations. It is possible
that AI/AN adults with diabetes have become more obese
during the study period just as U.S. adults have become
more obese. Treatment of diabetes may limit weight loss,
and some pharmacologic agents used to treat people with
diabetes are associated with weight gain (25). In longitudi-
nal studies among the Pima Indians of Arizona, pharma-
cologic treatment had a statistically significant limiting
effect on weight loss in people after the onset of diabetes
(26), and clinical trial data from the United Kingdom
Prospective Diabetes Study showed the greatest increase
in weight among people using insulin and certain pharma-
cologic agents (27). With more interest in using intensive
therapies since publication of the findings of the United
Kingdom Prospective Diabetes Study, which were released
during the study period, changes in treatment practice
toward improved glycemic control (10) could explain some
of the observed trends. Such treatment changes, however,
would not explain the increase in mean BMI found in
patients who were not treated with such agents (Table 3).
Alternatively, the observed increases in obesity could
reflect unintentional changes in who was included in the
DCOA or how the audit was conducted. For example, an
unrecognized selection bias toward participants with
greater BMIs or a bias toward collection of data from par-
ticipants with higher BMIs over time could create a tem-
poral trend. To examine this possibility, we analyzed the
percentage of participants who were missing BMI data
during the study period and did find that the percentage of
participants with missing data decreased from 17.6% in
1995 to 4.5% in 2004. However, the inclusion and exclusion
criteria remained the same during the study period and
never included weight restrictions, so the decrease in the
number of patients with missing BMI values likely reflects
better medical record documentation and less likely
reflects differences in data reporting or in participant
selection. Confounding due to other cohort differences is
also unlikely to explain the results because adjustment for
age, sex, diabetes duration, treatment type, and treatment
facility did not substantially change our observations.
Furthermore, the large dataset and the large number of
different auditors should limit the chance of a one-way sys-
tematic selection bias toward more obese patients for
inclusion. Still, changes based on modifications of health
care usage bias, diagnostic criteria, or case ascertainment
of diabetes cannot be fully excluded. Longitudinal studies
would be required to fully address these and other ques-
tions about the cause of our observations.
Health care programs can be tailored to meet the
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obesity. Options include dietary and physical activity
interventions with behavioral modification strategies,
antiobesity drugs, and, for certain individuals, surgical
interventions (28). Public health approaches to weight
management may also have a role, particularly if they are
combined with interventions directed at individuals (29).
By documenting increasing trends in obesity among people
with type 2 diabetes, this study helps to focus both clinical
and public health attention on a major health challenge
facing health professionals serving not only American
Indian and Alaska Native people but also Latino, African
American, and other communities that are experiencing
an increase in prevalence of obesity and type 2 diabetes
(30). The challenge will be to better understand the physi-
ologic, socioeconomic, and lifestyle factors influencing obe-
sity in adults with type 2 diabetes and to design, develop,
implement, and evaluate effective and culturally appropri-
ate interventions to address the trends in obesity in these
high-risk groups.
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Table 1. Selected Demographic and Clinical Variables From Representative Years of the Diabetes Care and Outcomes Audit
Among American Indian and Alaska Native Adults With Type 2 Diabetes, Indian Health Service, 1995–2004
Sex, no. (%)
Male 2780 (39.1) 4243 (39.8) 12,099 (42.4)
Female 4326 (60.9) 6408 (60.2) 16,409 (57.6)
Treatment type, no. (%)
Diet or exercise alone 1009 (14.2) 1292 (12.1) 5,476 (19.2)
Oral agent(s) 3397 (47.8) 6212 (58.3) 15,894 (55.8)
Insulin 2700 (38.0) 3147 (29.5) 6,846 (24.0)
Unknown or missing 0 0 292 (1.0)
Age at audit, y, mean (SD) 55.6 (13.4) 55.2 (13.6) 54.9 (13.8)
Duration of disease, y, mean (SD) 9.2 (7.6) 8.7 (7.5) 8.3 (7.3)
Age at onset, y 46.4 (13.2) 46.5 (13.2) 46.6 (13.4)
Body mass index, unadjusted mean (SD) 32.1 (6.7) 33.0 (7.0) 34.4 (7.8)
Body mass index, adjusteda mean (SD) 32.1 (0.1) 33.0 (0.1) 34.4 (0.1)
Men 31.3 (0.1) 32.1 (0.1) 33.7 (0.1)
Women 32.6 (0.1) 33.7 (0.1) 34.9 (0.1)
aAdjusted for age, sex, duration of diabetes, treatment type, and treatment facility.
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Table 2. Trends in Class of Body Mass Index by Sex Among American Indian and Alaska Native Adults With Type 2 Diabetes,
Diabetes Care and Outcomes Audit, Indian Health Service, 1995–2004
Class I (30.0-34.9 kg/m2)
All 2193 (30.9) 2261 (30.0) 2290 (30.3) 2814 (30.6) 3228 (30.3) 3234 (29.3) 4631 (29.8) 4905 (29.7) 6954 (28.6) 8232 (28.9) –6.5
Men 896 (32.2) 978 (32.7) 964 (31.2) 1201 (32.7) 1356 (32.0) 1407 (31.0) 2032 (31.5) 2186 (31.8) 3184 (31.1) 3766 (31.1) –3.4
Women 1297 (30.0) 1283 (28.3) 1326 (29.7) 1613 (29.2) 1872 (29.2) 1827 (28.1) 2599 (28.7) 2719 (28.2) 3770 (26.9) 4466 (27.2) –9.3
Class II (35.0-39.9 kg/m2)
All 1192 (16.7) 1329 (17.6) 1320 (17.5) 1618 (17.6) 1957 (18.4) 2063 (18.7) 2955 (19.0) 3261 (19.8) 4873 (20.1) 5814 (20.4) +22.2
Men 415 (14.9) 473 (15.8) 449 (14.5) 582 (15.8) 714 (16.8) 791 (17.4) 1189 (18.4) 1293 (18.8) 1938 (18.9) 2369 (19.6) +31.5
Women 777 (18.0) 856 (18.9) 871 (19.5) 1036 (18.8) 1243 (19.4) 1272 (19.6) 1766 (19.5) 1968 (20.4) 2935 (20.9) 3445 (21.0) +16.7
Class III (>40.0 kg/m2)
All 816 (11.5) 929 (12.3) 960 (12.7) 1343 (14.6) 1581 (14.9) 1710 (15.5) 2648 (17.1) 2926 (17.7) 4760 (19.6) 5784 (20.3) +76.5
Men 216 (7.7) 285 (9.5) 313 (10.1) 422 (11.5) 459 (10.8) 547 (12.1) 885 (13.7) 984 (14.3) 1603 (15.6) 2044 (15.6) +102.6
Women 600 (13.9) 644 (14.2) 647 (14.5) 921 (16.7) 1122 (17.5) 1163 (17.9) 1763 (19.4) 1942 (20.2) 3157 (22.5) 3740 (22.8) +64.0
All values are number (percentage) unless otherwise indicated.
Table 3. Adjusteda Mean (SE) of Body Mass Index by Treatment Type Among American Indian and Alaska Native Adults With
Diabetes, Diabetes Care and Outcomes Audit, Indian Health Service, 1995–2004
Diet or  32.3 (0.22) 32.5 (0.22) 32.4 (0.21) 33.1 (0.20) 33.2 (0.20) 33.0 (0.18) 32.8 (0.15) 33.4 (0.13) 33.4 (0.11) 33.8 (0.10) <.001
exercise alone
Oral agent(s) 32.1 (0.11) 32.3 (0.10) 32.6 (0.10) 32.9 (0.09) 33.0 (0.08) 33.1 (0.08) 33.6 (0.07) 33.9 (0.72) 34.4 (0.06) 34.6 (0.06) <.001
Insulin 32.0 (0.14) 31.8 (0.16) 32.4 (0.15) 32.9 (0.14) 31.6 (0.13) 33.2 (0.14) 33.6 (0.12) 33.8 (0.12) 34.1 (0.11) 34.1 (0.10) <.001
aAdjusted for age, sex, duration of diabetes, treatment type, and treatment facility.
bP value determined by analysis of covariance.
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